Seer, Inc. (NASDAQ:SEER), a company focused on proteomic analysis technology, reported its fourth quarter and full-year 2025 financial results after the market close on February 26, 2026. The report presented a mixed picture of modest revenue growth against a backdrop of significant ongoing losses and a cautious near-term outlook, leading to a sharp negative reaction in after-hours trading.
Earnings and Revenue Versus Estimates
The company's results for the critical fourth quarter came in below analyst expectations on the top line, while the bottom-line loss was slightly narrower than anticipated.
- Q4 2025 Revenue: Reported at $4.2 million, a 5% year-over-year increase but notably short of the analyst consensus estimate of $4.69 million.
- Q4 2025 EPS: Reported a net loss of $0.29 per share. This loss was less severe than the estimated loss of $0.33 per share.
For the full year 2025, Seer generated revenue of $16.6 million, representing 17% growth over 2024. The annual net loss improved to $73.6 million ($1.28 per share) from $86.6 million ($1.39 per share) in the prior year, driven largely by a significant reduction in operating expenses, particularly stock-based compensation.
Market Reaction and Guidance
The market's immediate response was decisively negative, with the stock falling over 13% in after-hours trading following the release. This reaction appears to be primarily fueled by the company's provided outlook for 2026, which fell well below existing analyst forecasts.
- Seer's 2026 Guidance: The company expects full-year 2026 revenue in the range of $16 million to $18 million. At the midpoint of $17 million, this represents only approximately 3% growth over 2025.
- Analyst Expectations for 2026: Prior to the report, analysts were modeling sales of approximately $22.5 million for the full year 2026. The company's guidance is roughly 24% below this consensus.
The stark disconnect between internal expectations and external analyst models suggests a more prolonged period of challenging market conditions than previously anticipated. In its release, CEO Omid Farokhzad cited "ongoing budgetary pressures" and "uncertainty around NIH funding" as persistent headwinds for its academic and research institution customers.
Key Highlights from the Report
Beyond the financial figures, Seer highlighted several operational milestones achieved in 2025, which point to continued, albeit slow, adoption of its Proteograph technology platform.
- Installed Base Growth: The company expanded its global installed base of instruments to 82, a 67% increase from the end of 2024, with 33 new instruments placed during the year.
- Scientific Validation: Seminal customer studies were published in high-impact journals like Nature and Nature Genetics, and the platform was featured in numerous presentations at major industry conferences.
- Strong Balance Sheet: Seer ended the year with a robust cash position of approximately $240.6 million in cash, cash equivalents, and investments. This provides a substantial runway to navigate the current challenging environment, though it declined from $299.5 million at the end of 2024.
- Expense Management: The company demonstrated improved cost control, reducing full-year operating expenses by 19% to $86.5 million and narrowing its operating and net losses year-over-year.
Looking Ahead
The core narrative emerging from Seer's earnings is one of a company facing a longer-than-expected sales cycle in a constrained funding environment. While it is successfully placing its proprietary instruments and gaining scientific credibility—critical for a life sciences tools company—the translation into meaningful near-term revenue growth remains muted. The guidance for minimal growth in 2026 signals that management does not see these customer budget pressures abating in the immediate future. Investors will be watching closely for signs of acceleration in consumable kit sales from the growing installed base and for progress in the company's initiatives around population-scale studies.
For a detailed look at Seer's historical earnings and future analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial advice, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
